L. Zhang

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)

Kim Papp, C. Leonardi, Andrew Blauvelt et al. · British Journal of Dermatology · 2017 · 94 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3

P.C.M. van de Kerkhof, Lyn Guenther, A.B. Gottlieb et al. · Journal of the European Academy of Dermatology and Venereology · 2016 · 82 citations

Medicine, Pharmacology, Pharmacotherapy +11

The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate‐to‐severe plaque psoriasis

Kristian Reich, L. Puig, Lotus Mallbris et al. · Journal of the European Academy of Dermatology and Venereology · 2017 · 43 citations

Medicine, Pharmacology, Pharmacotherapy +12

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from <scp>UNCOVER</scp>‐3 study

Mark Lebwohl, Kenneth B. Gordon, Gaia Gallo et al. · Journal of the European Academy of Dermatology and Venereology · 2019 · 32 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13